Clin2
NCT07438496Possibly a fitRecruiting

Study of nipocalimab for moderate to severe lupus

Lupus Erythematosus, Systemic

Treatments studied

Part of Immune system & allergy, Skin clinical trials.

This trial tests a new medicine, nipocalimab, for adults with moderate to severe lupus. It aims to see if the drug can help control lupus symptoms and reduce disease activity.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 3
Enrollment
600 people
Ages
18 years to 75 years
Study type
Interventional

Who can take part

  • You must have been diagnosed with lupus for at least 24 weeks.
  • Your lupus must be moderately to severely active, with a certain level of disease activity measured by a standard score.
  • You must have at least one organ system with high lupus activity or two systems with moderate activity.
  • You must be generally stable from a medical standpoint, including heart, lungs, and kidneys.
  • If you can become pregnant, you must have a negative pregnancy test before starting.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT03543839Recruiting· Phase 4
Belimumab for early lupus activity in the first two years

This trial tests belimumab to see if it can improve lupus (SLE) disease activity in people who were diagnosed within the last two years. You may be eligible if your lupus is currently mild to moderate and your background lupus medicines are stable.

Manhasset, New York
NCT06897930Recruiting· Phase 1/Phase 2
Testing a new drug for adults with lupus

This trial tests an investigational drug called AZD0120 in adults with lupus that hasn't improved with standard treatments. The goal is to see if it's safe and works well for people with lupus-related organ problems.

San Francisco, California
NCT07748156Not yet recruiting· Early Phase 1
SNC116 for severe lupus that hasn't improved with standard care

This trial tests a new treatment called SNC116 for people with severe lupus who haven't gotten better with standard medicines. It aims to reduce lupus activity by targeting certain immune cells.

Nanjing, Jiangsu
NCT07177911Recruiting· Phase 1
Study of CC312 for moderate to severe lupus

This trial tests a new medicine called CC312 for people with moderate to severe lupus (SLE) that hasn't improved with standard treatments. The goal is to see if it is safe and can help control the disease.

Chengdu, Sichuan
NCT07175285Recruiting
Study for lupus patients not helped by steroids and 2 immunosuppressants

This trial tests a new treatment for people with active lupus who haven't responded well to steroids and at least two other immune-suppressing drugs, including a biologic. It aims to find a better option for controlling lupus symptoms.

Mesa, Arizona
NCT06857214Recruiting· Phase 1
GNC-038 antibody study for moderate to severe lupus

This trial tests a new antibody treatment, GNC-038, for people with moderate to severe lupus. It aims to see if it's safe and effective. You must have stable lupus treatment and active B cells in your blood.

Shanghai, Shanghai Municipality

Hear when a new Lupus Erythematosus, Systemic trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.